- Global Pharma News & Resources

Drug Repurposing Market to witness CAGR outstanding 3.4% CAGR from 2023 to 2032

The size of the global market for Drug Repurposing was projected to be US$ 25.2 billion in 2021 and is anticipated to increase at a CAGR of 3.4% from 2023 to 2032.

Drug repurposing, also known as drug reprofiling, helps businesses to identify fresh clinical uses for already-available medications. All licensed, archived, and experimental medications can be used in new ways.

Access the sample report:

The key players of the Global Drug Repurposing Market are:

Astellas Pharma, Sanofi, GSK, Exscientia Limited, Atomwise Inc, Biovista Inc, Centene Corp (Health Net, LLC), NuMedii Inc, SOM Innovation Biotech S.A., Pfizer Inc, Recursion Pharmaceuticals Inc, Healx, Johnson & Johnson, Sosei Group Corp (SoseiHeptares), plc, and others include important participants in the drug repurposing market.

Why drug repurposing is beneficial for pharmaceutical companies?

Pharmaceutical companies have a sizable stockpile of abandoned, unsuccessful, and terminated medications. This serves as a collection of exclusive substances that can be regarded as intellectual property. By using them to treat new diseases, a lot of these candidate molecules can be conserved.

Additionally, pharmaceutical firms have access to a sizable amount of information from studies on medication combinations and clinical studies. This information can be used to monitor the indications and targets that their current pharmacological portfolio is most effective at treating.

Such medication recovery and conversion techniques offer the pharmaceutical industry a fantastic chance to optimize its portfolio by profitably reviving lost or abandoned medicinal ventures.

Global drug repurposing market is expanding:

Drugs that have been repurposed may allow the pharmaceutical industry to expand its current drug discovery business. Enhanced life cycles and patent administration for older pharmaceuticals are also made possible by drug repurposing.

The duration of the medication development process is shortened for reused ingredients because the physicochemical and production procedures are already well-established.

Read more about the report inclusions:

The strongest prospects for drug repurposing are medications that have already passed pre-clinical and clinical testing for use in different disorders. Such medications will at the very least require simple efficacy tests and research on how they interact with diseases.

Similar to this, many pre-clinical tests, bio-safety evaluations, and phase 1 clinical studies can be skipped for medicines that are already licensed and on the market in the event that new targets are found.

If it is discovered that the majority of the medications that have been shelved or terminated are effective versus unidentified targets, their current interaction data, molecular characterization, and manufacturing techniques can be applied again.

Although they will ultimately need to comply with all regulations, the R&D parts will be hassle-free. To find repurposed pharmaceuticals, both business and governmental drug development organizations can apply systematic, data-driven methodologies and computational biology/bioinformatics.

A number of effective instances, including aspirin, sildenafil, and minoxidil, have demonstrated the effectiveness of drug repurposing.

Benefits of drug repurposing:

Drug repurposing is a powerful tool for finding treatments for undiagnosed or understudied diseases. For such disorders or disorders, whose pathophysiology is occasionally poorly defined, computational approaches for predictive repurposing offer a quick way to uncover probable alternatives.

It may be possible to swiftly repurpose drugs that target the related protein or pathways using a large-scale genome-sequencing method to identify the genetic changes causing the condition.

Therefore, repurposing such medications may be transferred directly into quick clinical trials even without engaging in wet-lab experiments, all without the need for preliminary research. Some recently discovered bioactive substances might not tolerate high plasma concentrations or have poor potencies.

Existing drugs can operate better or promote tolerance when combined in synergistic ways. Such drug repurposing procedures can also be used in conjunction with cancer chemotherapies.

Contrary to monotherapies, combination medication treatments offer one of the broadest research opportunities for drug repurposing. In the case of combinatorial treatments, the likelihood of discovering a potential application for an existing medicine increases dramatically.

Therefore, the most logical and straightforward strategy in this field is to completely replace medications used in monotherapy or co-treatment with repurposed drugs. Due to the prominence of combination medications in medical therapy in recent years, this method has demonstrated significant potential.

Drug repurposing can be effectively investigated for spectrum diseases that call for a patient-specific treatment regimen.

Expanded combinatorial techniques will be necessary for clinical uses tailored to specific variances in the genome, transcription, proteomics, and metabolic activity, which can be made possible through drug repurposing.

Global Drug Repurposing Market Key Segments:

By Types

  • Disease-centric
  • Drug-centric
  • Target-centric

By Therapeutic Area

  • Similar Therapeutic Area
  • Dissimilar Therapeutic Area

By Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Regulations and restriction on drug development can enable better outcomes for drug repurposing market:

Legal restrictions on drug repurposing can hinder scientific advancements. There are a number of challenges involved in patent protection a novel use for an already-patentable medicine.

Before conducting repurposing research, consent from the holders of any pending patents will be needed; even if a new candidate is proven to be effective, there may be issues with patent sharing or royalties. As a result, third parties have less incentive to repurpose drugs for illicit purposes.

Proceed to purchase:

Existing medications have a wide range of specialist literature or possible uses that are widely understood. Many medications are often used off-label or unregistered in clinical settings. The originality and design patents of repurposed medications may potentially be impacted by this.

To efficiently combine huge amounts of data, functional and structural investigations, clinical trial paperwork, and tools based on genomics and proteomics, technological breakthroughs are needed in many different domains.

Humans won’t be able to successfully track pharmacological action for unidentified targets unless all of these areas are coherent.

Major diseases can be tackled through use of repurposed drugs:

The method of drug repurposing can also help treat uncommon or undertreated conditions and diseases. By using repurposed medications, appealing incentives for various ailments can be created in an area with poor economic prospects.

Although some health domains might not be economically beneficial, other types of value, such as a company’s social responsibility could be attained by such efforts. Pharmaceutical research for such uncommon or neglected diseases is made possible by taxpayer subsidies, tax exemptions, regulatory fee exemptions, and fast-track approval.

By reusing currently available medications without spending money on R&D, drug repurposing can assist the pharmaceutical industry in overcoming financial barriers.

Drug repurposing strategies can address drug administration simplicity. It is possible to create therapies or choose combination bioactive chemical therapies from already available medications.

Repurposed drugs that are simple to give, take less time to treat people, and protect against the emergence of the resistant causal organism can take the role of effective but complex medicines.

Related reports:

Global Feed Mixer Market:

Global Bronchoscope Market:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 30-Jan-2023